



Europäisches Patentamt
European Patent Office
Office européen des brevets



⑪ Publication number: 0 563 813 A1

⑫

EUROPEAN PATENT APPLICATION

⑬ Application number: 93105010.8

⑭ Int. Cl. 5: A61K 31/12, A61K 31/215,
A61K 47/10, A61K 47/14

⑮ Date of filing: 26.03.93

⑯ Priority: 30.03.92 US 859745

⑰ Applicant: HOECHST-ROUSSEL
PHARMACEUTICALS INCORPORATED
P.O. Box 2500,
Route 202-206
Somerville, NJ 08876-1258(US)

⑰ Date of publication of application:

06.10.93 Bulletin 93/40


⑱ Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU NL
PT SE

⑲ Inventor: Kwon, Kim H.
21 Muirfield Lane
Bridgewater, New Jersey 08807(US)
Inventor: Koplowitz, Barry
176 Capricorn Drive
Somerville, New Jersey 08876(US)
Inventor: Henderson, Norman L.
6 Patriot Road,
Gladstone
New Jersey 07934(US)

⑳ Representative: Becker, Heinrich Karl
Engelbert, Dr. et al
HOECHST AKTIENGESELLSCHAFT,
Zentrale Patentabteilung,
Gebäude F 821
D-65926 Frankfurt am Main (DE)

㉑ Transdermal compositions.

㉒ Novel compositions comprising an antiandrogenic compound of the formula



wherein R is COR₁ wherein R₁ is loweralkyl and a vehicle comprising a metabolism modulator and a polar organic solvent, are disclosed.


EP 0 563 813 A1

The present invention relates to a pharmaceutical composition comprising an antiandrogenic tricyclic compound of formula 1

5

10

15



wherein R is COR₁, wherein R₁ is loweralkyl and a vehicle comprising a metabolism modulator and a polar organic solvent.

The skin, the largest organ of the mammalian body, having a surface area of about two square meters, provides a fertile field for the topical, local, and systemic administration of medicaments. Applied to the skin, medicaments elicit topical effects on the surface and in the horny layer, the stratum corneum, the barrier to skin penetration. Medicaments that surmount this barrier elicit local effects in the epidermis, and those which further penetrate the skin into the dermis enter the microcirculation and eventually the general circulation to elicit systemic effects. Control of the penetration of a medicament into the epidermis or dermis to achieve therapeutic levels of the agent for desired topical or systemic effects, respectively, is generally hindered by the poor diffusion characteristics of most medicaments in the skin and by biotransformations, primarily in the epidermis, leading to metabolites having greater or lesser pharmacological activity, toxicity, or retention properties than the precursor. To improve the diffusion characteristics of medicaments in skin, membrane penetration enhancers such as amides, lactams, and sucrose, and glycerol monofatty acid esters have been employed in admixtures with the medicaments. Such enhancers promote percutaneous transport across the stratum corneum thereby facilitating passage into the viable epidermis/dermis region of the skin. See U.S. Patent 4,808,414 issued February 28, 1989, U.S. Patent 3,969,516 issued July 13, 1976, and U.S. Patent 4,788,062 issued November 29, 1988, respectively, for a discussion of the roles played by amides, lactams, and fatty acid esters as penetration enhancers. Alcohols, such as ethanol, 2-propanol, and the like, have also been used as vehicles for the administration of medicaments to skin to obtain high rates of transport for systemic treatment of various disorders. See U.S. Patent 4,804,541 issued February 14, 1989.


To modulate biotransformations in the skin, particularly enzymatic hydrolysis in the epidermis/dermis regions of the skin, esterase inhibitors have been utilized. One such inhibitor, diisopropylfluorophosphate, which has been found to efficiently limit enzymatic hydrolysis of medicaments, e.g., salicylate esters in skin, suffers from being highly toxic. See R. O. Potts, et al., Pharmaceutical Research, 6, 119 (1989).

It has now been found that compositions comprising a polar organic solvent and a metabolism modulator provide a vehicle for controlling the rate and extent of membrane permeation and degree of metabolic conversion of topically administered antiandrogenic tricyclic esters of formula 1

45

50

55



wherein R is COR₁ wherein R₁ is loweralkyl by modulating the metabolic and modifying the transport properties of mammalian skin, mucosa, or other permeable membranes, thereby attaining the objectives of the present invention, namely, to enhance the percutaneous delivery of tricyclic esters 1 (wherein R is COR₁ wherein R₁ is loweralkyl) through mammalian membranes, to modify the metabolic conversion of tricyclic esters 1 (wherein R is COR₁ wherein R₁ is loweralkyl) to tricyclic alcohols 1 wherein R is hydrogen (i.e., to control the dermal biotransformation of, e.g., 3 β -acetoxy-6-ethyl-3 α β -methyl-1,2,3,3a,4,5,8,9a,9b-decahydro-7H-benz(e)inden-7-one, incocerone acetate (wherein R is COR₁ wherein R₁ is methyl) to the more active metabolite, 6-ethyl-3 α β -methyl-1,2,3,3a,4,5,8,9a,9b-decahydro-7H-benz(e)inden-3-ol-7-one, incocerone (wherein R is COR₁ wherein R₁ is hydrogen), and to regulate the rate of permeation of topically applied tricyclic ester 1 (wherein R is COR₁ wherein R₁ is loweralkyl) so as to reduce or eliminate systemic effects of the medicament.

As used through the specification and appended claims, the term "alkyl" refers to a straight or branched chain hydrocarbon containing no unsaturation and having 1 to 8 carbon atoms such as methyl, ethyl, 1-, 2-propyl, butyl, 1-pentyl, 3-hexyl, 4-heptyl, 2-octyl, and the like, unless specified otherwise. The term "lower" as applied thereto refers to a group having up to and including 6 carbon atoms.


Control of the rate and extent of membrane penetration and degree of metabolic conversion is achieved by selecting a vehicle comprising the appropriate polar organic solvent and metabolism modulator, and varying the proportion of polar organic solvent and metabolism modulator in the vehicle. Thus, for example, control of the rate and extent of membrane penetration and degree of metabolic conversion is achieved by employing a carbinol of the formula R₂OH wherein R₂ is alkyl of 1 to 12 carbon atoms, such as those described above and 1-nonyl, 2-decyt, 3-undecyl, dodecyl, and the like, or alkenyl of 3 to 12 carbon atoms, such as propenyl, 2-butenyl, 2-pentenyl, 2-hexenyl, 3-heptenyl, 4-octenyl, 4-nonenyl, 5-deceny, 5-undecenyl, 6-dodecenyl, and the like, or a ketone of the formula

25



30 wherein R₃ and R₄ are independently alkyl of 1 to 4 carbon atoms, or mixtures thereof, as the polar organic solvent, and an ester of an aliphatic monocarboxylic acid of the formula R₅CO₂R₆ wherein R₅ and R₆ are independently alkyl or alkenyl having a total of 3 to 35 carbon atoms, and mixtures thereof, or a diester of an aliphatic dicarboxylic acid of the formula R₇(CO₂R₈)₂ wherein R₇ is as above and R₈ is alkyl or alkenyl having a total of 5 to 46 carbon atoms, or mixtures thereof, or a triester of glycerol of the formula

35



45

wherein R₈, R₉ and R₁₀ are independently alkyl or alkenyl having a total of 3 to 54 carbon atoms, as the metabolism modulator. Esters of aliphatic monocarboxylic acids include ethyl acetate, cetyl acetate, myristyl acetate, ethyl laurate, propyl laurate, butyl laurate, isopropyl myristate, isopropyl palmitate, ethyl oleate, decyl oleate, ethyl linoleate, ethyl linolenate and the like; diesters of aliphatic dicarboxylic acids include diethyl succinate, dibutyl adipate, dihexyl adipate, dicapryl adipate, diethyl sebacate, diisopropyl sebacate, dibutyl sebacate, diethyl sebacate, and the like; triesters of glycerol include glyceryl triacetate, glyceryl tri laurate, glyceryl trimyristate, glyceryl tripalmitate, glyceryl trioleate, glyceryl tri linoleate, and the like, as well as triglycerides of coconut oil fatty acids having 8 to 10 carbon atoms, such as \circledR Miglyol 810 and \circledR Miglyol 812 available from Dynamit Nobel of America, Inc., 105 Stonehurst Court, Northvale, New Jersey 07647. Preferred aliphatic monocarboxylic acid esters include isopropyl myristate, ethyl laurate, propyl laurate, butyl laurate, isopropyl palmitate and ethyl oleate, isopropyl myristate being most preferred.

Carbinols include ethanol, 1- and 2-propanol, 1-butanol, 2-pentanol, 3-hexanol, 1-heptanol, 2-octanol, 3-nananol, 1-decanol, 1-undecanol, 1-dodecanol, and the like.

Ketones include acetone, 3-pentanone, 4-heptanone, 5-nonanone, and the like. Ethanol, including 95% ethanol and 2-propanol, and acetone are the preferred carbinol and ketone, respectively, ethanol being most preferred.

To achieve the objects of the present invention, a tricyclic compound of formula 1 wherein R is COR₁ wherein R₁ is loweralkyl is dissolved in a vehicle comprising a metabolism modulator and a polar organic solvent, and the composition is applied to mammalian skin, mucosa, or other membrane tissue. The metabolism modulator is generally present in the amount of about 0.5 to about 99.5% by weight of the vehicle, the amount of polar solvent, by necessary, being from about 99.5 to 0.5% by weight of the vehicle. While the amounts of metabolism modulator and polar solvent are not narrowly critical within the aforementioned ranges, the presence of both modulator and solvent is necessary to achieve the stated objectives. The amount of antiandrogenic tricyclic ester 1 wherein R is COR₁ wherein R₁ is loweralkyl admixed with the vehicle is such that the desired pharmacological effect, antiandrogenic activity, is achieved over the desired time period. Generally, the amount of ester 1 wherein R is COR₁ wherein R₁ is loweralkyl admixed with the vehicle falls within the range of from about 0.1 to about 40% by total weight of the vehicle, most preferably about 0.5 to about 20% by total weight of the vehicle.

The compositions of the present invention may be applied directly to membrane tissue or may be incorporated into a solution, suspension, ointment, cream, lotion, gel, or plastic, using conventional inert excipients (carriers). These pharmaceutical compositions should contain at least 0.1% of the active composition; the amount may vary, however, between about 0.1% and about 20% of the weight thereof. 20 The amount of active composition in the pharmaceutical formulation is such that a suitable dosage is obtained. For the formulation of solutions the compositions of the present invention may be dissolved in glycerin, propylene glycol, polyethylene glycols, or other synthetic solvents, and the solution may be applied directly to the skin, or adsorbed onto a cotton pad, sterile gauze, or porous membrane and applied topically. The suspensions, creams, lotions, and gels may contain emulsifying and/or solubilizing agents 25 such as acacia, glyceryl monostearate, lecithin, Poloxamer brand of polyoxyethylene, polyoxypropylene block polymer available from BASF Wyandotte Corporation, 1809 Biddle Avenue, Wyandotte, MI 48192, polysorbates, Spans brand of sorbitan mono- and tri-fatty acid esters available from ICI America Inc., Wilmington, DE 19899, and the like, and suspending and/or viscosity-increasing agents such as agar, alginic acid, aluminum monostearate, ©Carbopol 940 or ©Carbomer 934P brand of polyacrylic acid 30 available from B.F. Goodrich Chemical Co., 8100 Oak Tree Blvd., Cleveland, OH 44131, sodium carboxymethylcellulose, carrageenan, dextrin, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxethyl cellulose, methylcellulose, pectin, polyethylene oxide, Povidone brand of polyvinylpyrrolidone available from GAF Corporation, 1361 Alps Road, Wayne, NJ 07470, propylene glycol alginate, tragacanth and the like, and ointment bases such as lanolin, polyethylene glycol, petrolatum, squarene and the like, 35 and humectants such as glycerin, propylene glycol, sorbitol and the like, in an amount of about 1 to about 10% by weight of the formulation.

The antiandrogenic compounds of the compositions of the present invention as prepared by the processes described in U.S. Patent Nos. 4,466,971, 4,807,054, and 4,849,454, issued August 21, 1984, August 19, 1986, and July 18, 1989, and are reported to be useful for the treatment of acne, hirsutism, seborrhea, among other, afflictions due to hyperandrogenicity.

The invention is further illustrated by the following examples which are illustrative of a specific mode of practicing the invention and is not intended as limiting the scope of the appended claims.

EXAMPLE 1

In Vitro Skin Permeation and Metabolism Studies

The freshly excised hairless mouse skin was used in the two-compartment diffusion cell method of Chien et al., Drug Development and Industrial Pharmacy, 11, 1333-1173 (1985). The hairless mouse (HRS/J strain) was sacrificed just prior to the experiment by cervical dislocation. A square section of the abdominal skin was surgically removed and mounted between two side-by-side half cells; the exposed area of the skin being approximately 0.64 cm². A 1-10% weight/volume (w/v) solution of inocoterone acetate and vehicle was added to the donor compartment and a 40% w/v polyethylene glycol 400/normal saline solution was added to the receptor compartment. Simultaneous skin permeation and biotransformation studies were conducted in a thermostated diffusion cell apparatus at 37 °C. At appropriate intervals samples were withdrawn from the receptor compartment and analyzed for inocoterone acetate and its metabolite, inocoterone, by high pressure liquid chromatography. No significant hydrolysis of the inocoterone acetate in the blank receptor solution was noted during the time course of the permeation experiment. Each

experiment was carried out in at least triplicate. This method was used in Examples 3 to 6.

For the evaluation of pharmaceutical compositions of the present invention, the freshly excised hairless mouse skin was used in the diffusion cell method of Franz, *Current Problems in Dermatology*, 7, 58-68 (1978), in a vertical position, the exposed area of the skin being approximately 1.8 cm². The pharmaceutical formulation of known concentration in vehicle was added to the upper compartment of the cell, which was exposed to the stratum corneum side of the skin, and a 40% polyethylene glycol 400/normal saline solution was placed in the lower compartment. The penetration and metabolism rates were studied in a thermostated diffusion cell at 37 °C using the analytical method described above. Each experiment was carried out in at least triplicate. This method was used in Examples 7 and 13.

10

EXAMPLE 2

In Vivo Antiandrogen Activity Test - Rat

15

Male rats (intact or castrated) were treated topically with specified doses of inocoterone acetate solution in various solvent systems on days 1, 2, 3, 6 and 7 of each week for 1 to 3 weeks. The castrated rats received daily injections of testosterone propionate (250 µg/day) subcutaneously. One day after the last administration, the animals were sacrificed and fragments of the skin and prostates were removed. The skin fragments were prepared for quantitative measurement of volume density of smooth endoplasmic reticulum (SER) by means of electron microscopy and the prostates were weighed. The studies using intact rats and castrated rats stimulated with testosterone propionate demonstrated a dose related reduction in volume density of SER with inocoterone acetate at a dose range from 0.25 to 25 mg/rat/day, whereas there was no significant effect on prostate weight at any dose.

20

EXAMPLE 3

25

Compositions of 10% w/v of inocoterone acetate in vehicle solutions were prepared by dissolving 1 g of the medicament in 10 ml of a mixture of isopropyl myristate and 95% ethanol in the following volume percent ratios: 100:0, 95:5, 70:30, 60:40, 50:50, 40:60, 30:70, 5:95 and 0:100, respectively. The in vitro skin permeation and metabolism rates were measured using the method described under the in vitro skin permeation test method. The results of these measurements, in terms of the cumulative amount of unchanged medicament and its metabolite permeated in -moles per square centimeter with time, over 5 hours are given in Fig. 1.

30

The procedure of Example 3 was repeated except that the mixtures comprised isopropyl myristate and acetone in the following volume percent ratios: 100:0, 80:20, 50:50 and 20:80, respectively. The simultaneous skin permeation and metabolism rates generated from these medicament solutions using the method described in Example 1 are given in Fig. 2.

35

EXAMPLE 4

40

The procedure of Example 3 was repeated except that the mixtures comprised isopropyl myristate and isopropyl alcohol in the following volume percent ratios: 100:0, 80:20, 50:50, 20:80 and 0:100, respectively. The simultaneous skin permeation and metabolism rates generated from these medicament solutions using the method described under Example 1 are given in Fig. 3.

45

EXAMPLE 5

50

In this example, isopropyl myristate is used as a metabolism modulator in combination with a polar organic solvent having various polarities (dielectric constants) in a 50:50 volume percent ratio for the evaluation of the skin permeation and metabolism rates of inocoterone acetate. The relationship between the percent metabolite determined based on the total medicament permeated in the first 5 hour time period and the dielectric constant of the polar organic in the solvent mixtures is given in Fig. 4.

55

EXAMPLE 6

In this example, the results of the use of ethanol as the polar organic solvent in combination with various fatty acid esters for the simultaneous skin permeation and metabolism of inocoterone acetate solution are shown.

Transdermal Flux Q ₁ ($\times 10^2$ μ moles/cm ² /5 hrs)				
Vehicle	Inocoterone Acetate	Inocoterone	Total Inocoterone	% Metabolite
Ethanol	0	1.1	1.1	100.0
10% Ethyl laurate -90% Ethanol	28.1	58.3	86.4	67.5
10% Propyl laurate -90% Ethanol	25.8	60.8	86.6	70.2
10% Butyl laurate -90% Ethanol	39.9	54.5	94.4	57.7
10% Isopropyl palmitate -90% Ethanol	9.4	27.5	36.9	74.5
10% Ethyl oleate -90% Ethanol	18.5	36.6	55.1	66.4

EXAMPLE 7

A composition, in the form of a gel, suitable for topical application of inocoterone acetate is prepared by mixing the following components in the given concentrations.

Component	Weight %
Inocoterone acetate	1-10
Butyl laurate	5-20
Ethanol	10-50
Polyacrylic acid (@Carbopol 904)	0.5-2
Triethanolamine (neutralizing agent)	q.s.
Sorbic acid (preservative)	q.s.
Deionized water	q.s. to 100

EXAMPLE 8

Ethyl laurate, propyl laurate, isopropyl myristate, isopropyl palmitate, diethyl sebacate, ethyl oleate, isopropyl laurate, diisopropyl sebacate, and the like, may be substituted for butyl laurate in Example 7, to provide a topical composition suitable for the topical delivery of inocoterone acetate.

EXAMPLE 9

A polar organic solvent, e.g., n-propanol or isopropanol, is substituted for ethanol in Example 7, to provide a topical composition suitable for the topical delivery of inocoterone acetate.

EXAMPLE 10

A neutralizing agent, e.g., triethylene amine, sodium hydroxide or @Ethomeen C/25 brand of polyethylene glycol amine of coconut acid available from Akzo Chemical Co., 8201 West 47th Street, McCook, IL 60525, may be substituted for triethanolamine in Example 7, to provide a topical gel preparation suitable for the percutaneous delivery of inocoterone acetate.

EXAMPLE 11

A pharmaceutical composition in the form of a cellulose gel is prepared by mixing the following components in the following given concentrations:

Component	Weight %
Inocoterone acetate	1-10
Butyl laurate	10-50
Ethanol	5-20
Sorbic acid (preservative)	q.s.
Hydroxypropyl cellulose	1-5
Deionized water	q.s. to 100

5

EXAMPLE 12

A cellulose-type gelling agent, e.g., hydroxypropyl methylcellulose, hydroxyethyl cellulose, or sodium carboxymethyl cellulose may be substituted for hydroxypropyl cellulose of Example 11 to provide a topical composition suitable for the dermal delivery of inocoterone acetate.

EXAMPLE 13

In this example the simultaneous skin permeation and metabolism rates of inocoterone acetate incorporated in the [®]Carbopol 940 gels formulated using the compositions described in Example 7 are shown.

25

30

35

40

45

50

55

Composition	Percent w/w	Transdermal Flux $Q_1 (\times 10^2 \mu\text{moles}/\text{cm}^2/5 \text{ hours})$				% Metabolite
		Inocoterone Acetate	Total Inocoterone Acetate	Inocoterone	Inocoterone Acetate	
Inocoterone acetate	10.0	36.2	62.8	99.0	63.4	
Isopropyl myristate	6.0					
Ethanol	50.0					
Carbopol 940	0.7					
Triethanolamine	0.3					
Deionized water	33.0					
Inocoterone acetate	10.0	38.4	52.7	91.1	57.8	
Ethyl laurate	6.0					
Ethanol	50.0					
Carbopol 940	0.7					
Triethanolamine	0.3					
Deionized water	33.0					
Inocoterone acetate	10.0	45.2	66.2	111.4	59.4	
Butyl laurate	6.0					
Ethanol	50.0					
Carbopol 940	0.7					
Triethanolamine	0.3					
Deionized water	33.0					

EXAMPLE 14


In this example, the comparative effect of the vehicle systems of ethanol and a 40% isopropyl myristate-60% ethanol mixture on the in vivo efficacy of inocoterone acetate on the rat sebaceous gland is shown. The medicament in a dose of 0.5 mg/cm²/day for 5 days in 5 cm² area was applied to the skin of testosterone propionate-treated castrated rats using the solvent systems described above. From the isopropyl myristate-ethanol system, inocoterone acetate completely inhibited the testosterone-induced increase in the volume density of the smooth endoplasmic reticulum vesicles in the intermediate cells on the rat sebaceous gland. When the same dose of inocoterone acetate was applied using ethanol as the solvent, the effects of testosterone on the sebaceous gland were inhibited by 60%. Topical administration of the medicament with the isopropyl myristate-ethanol mixture resulted in a systemic antiandrogenic effect as evidenced by changes in the prostate.

The greater efficacy of inocoterone acetate when applied in the isopropyl myristate-ethanol mixture is consistent with the increased transcutaneous penetration observed in Example 3.

Claims

1. A pharmaceutical composition comprising an antiandrogenic tricyclic compound of the formula I

5



I

10


wherein R is COR₁; wherein R₁ is loweralkyl, a vehicle comprising a metabolism modulator and a polar organic solvent, and a suitable carrier therefor.

15

2. A pharmaceutical composition according to claim 1 wherein the metabolism modulator is a compound of the formula R₅CO₂R₆ wherein R₅ and R₆ are independently alkyl or alkenyl having a total of 3 to 35 carbon atoms; a compound of the formula R₇(CO₂R₈)₂ wherein R₇ is as defined above and R₈ is alkyl or alkenyl having a total of 5 to 46 carbon atoms; or a compound of the formula

20

25



30

wherein R₈, R₉, and R₁₀ are independently alkyl or alkenyl having a total of 3 to 54 carbon atoms or mixtures thereof, and wherein the polar organic solvent is a compound of the formula R₂OH where R₂ is alkyl of 1 to 12 carbon atoms or alkenyl of 3 to 12 carbon atoms, or a compound of the formula

35



wherein R₃ and R₄ are independently alkyl of 1 to 6 carbon atoms, or mixtures thereof..


40

3. A pharmaceutical composition according to claim 2, wherein the metabolism modulator of the formula R₅CO₂R₆ is selected from the group consisting of ethyl acetate, cetyl acetate, ethyl laurate, myristyl acetate, ethyl laurate, propyl laurate, butyl laurate, isopropyl myristate, isopropyl palmitate, ethyl oleate, decyl oleate, ethyl linoleate, and ethyl linolenate.
- 45
4. A pharmaceutical composition according to claim 2 wherein, the metabolism modulator of the formula R₇(CO₂R₈)₂ is selected from the group consisting of diethyl succinate, dibutyl adipate, dihexyl adipate, dicapryl adipate, diethyl sebacate, diisopropyl sebacate, dibutyl sebacate, and dioctyl sebacate.

50

5. A pharmaceutical composition according to claim 2, wherein the metabolism modulator of the formula

55



is selected from the group consisting of \circledcirc Miglyol 810 and \circledcirc Miglyol 812.

6. A pharmaceutical composition according to claim 2, wherein the polar organic solvent is ethanol, 2-propanol or acetone.
- 5 7. A pharmaceutical composition according to claim 1, wherein R₁ is methyl, the metabolism modulator is isopropyl myristate and the polar organic solvent is ethanol.
- 10 8. A pharmaceutical composition according to claim 1, wherein the carrier is a gelling agent.
9. A pharmaceutical composition according to claim 1, wherein the weight percent of the metabolism modulator is from about 0.5 to about 99.5 % of the vehicle.
- 15 10. A pharmaceutical composition according to claim 1, wherein the weight percent of the compound of the formula 1 is about 0.1 to about 40 % of the vehicle.

20

25

30

35

40

45

50

55



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 93 10 5010

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
D,A	EP-A-0 059 146 (ROUSSEL-UCLAF) * claims 1-11 * * page 3, line 36 - line 39 * * page 4, line 5 - line 28 * * examples 18-19 *	1-10	A61K31/12 A61K31/215 A61K47/10 A61K47/14

			TECHNICAL FIELDS SEARCHED (Int. Cl.5)
			A61K
The present search report has been drawn up for all claims			
Place of search THE HAGUE	Date of completion of the search 10 JUNE 1993	Examiner SCARPONI U.	
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : document used G : non-written disclosure F : intermediate document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : document used G : non-written disclosure F : intermediate document		A : member of the same patent family, corresponding document	